The therapeutic peptides Pep-H6 and Pep-G3, which recognize extracellular S100A8/A9 on MDSCs surface, could completely deplete blood and intra-tumoral MDSCs, thus enhancing the antitumor immunity of tumor-bearing mice and inhibiting tumor growth in vivo, indicating an emerging treatment direction for S100A8/A9 together with immune evasion (Qin et al., 2014). Here, IGKV1D-22 is linked to neoplasm.